Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Parastoo Khoshakhlagh
AddedMar 31, 2024
UpdatedMay 31, 2026
Parastoo Khoshakhlagh

Parastoo Khoshakhlagh

Founder & CEO, GC Therapeutics

CrunchbaseLinkedIn

Parastoo Khoshakhlagh's Career

GC Therapeutics
GC Therapeutics

Boston, MA, US

Founder & CEO· C-Suite · Management
Tympanogen
Tympanogen

Richmond, VA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Parastoo Khoshakhlagh's Career

GC Therapeutics
GC Therapeutics
Seed$339.9k202019Boston, MA, US
Founder & CEO· C-Suite · Management

Similar to GC Therapeutics

Garuda TherapeuticsGaruda TherapeuticsCambridge, MA, USStem Cell Therapiesest. 2021Garuda TherapeuticsCambridge, MA, US · est. 2021

Garuda Therapeutics: Developing ready-to-use stem cell therapies for severe diseases.

Series B · $134M67
Satellite BioSatellite BioCambridge, MA, USImplantable Organsest. 2019Satellite BioCambridge, MA, US · est. 2019

Satellite Bio: Pioneering off-the-shelf implantable organs through advanced cell and synthetic biology.

Series A · $101.5M47
Think BioscienceThink BioscienceBoulder, CO, USMedicinesest. 2019Think BioscienceBoulder, CO, US · est. 2019

Think Bioscience innovates synthetic biology, designing superior medicines using living systems.

Seed · $17.3M26
GentiBioGentiBioCambridge, MA, USBiotherapeuticsest. 2020GentiBioCambridge, MA, US · est. 2020

GentiBio, Inc.: Pioneering biotherapeutics with engineered T cells to treat immune and allergic diseases.

Series A · $177M176
Tympanogen
Tympanogen
Pre-Seed$3.3M82014Richmond, VA, US
Co-Founder

Leadership at Tympanogen

Elaine Horn-RanneyElaine Horn-RanneyCo-Founder
Jesse RanneyJesse RanneyCo-Founder

Similar to Tympanogen

EntratympanicEntratympanicMedfield, MA, USMedical Devicesest. 2009EntratympanicMedfield, MA, US · est. 2009

Founded in 2009, Entratympanic LLC is a medical device company specializing in biological R&D.

Seed · $25k6
ENT SurgicalENT SurgicalStow, OH, USSurgical Devicesest. 2009ENT SurgicalStow, OH, US · est. 2009

ENT-Surgical's Myringo device enables quick, local anesthesia-based myringotomy and tube insertion outside OR settings.

Seed · $400k5
PionEar TechnologiesPionEar TechnologiesAllston-Brighton, MA, USMedical Devicesest. 2018PionEar TechnologiesAllston-Brighton, MA, US · est. 2018

PionEar Technologies: Innovating medical devices for ear and hearing disorders.

Angel · $50k10
AuricleAuricleSan Francisco, CA, USest. 2020AuricleSan Francisco, CA, US · est. 2020

Auricle: Innovating neurostimulation implants to restore hearing, less invasive than cochlear implants.

Seed · $125k5

People Similar to Parastoo Khoshakhlagh

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoDennis McCulloughDennis McCulloughCEO · GC Innovation AmericaLawrence Eric GolubLawrence Eric GolubBoard Member · Golub CapitalPablo GalvanPablo GalvanCEO · GC1 VenturesBen MillenBen MillenCEO · GcsaPaolo PaolettiPaolo PaolettiBoard Member · GenmabJack BaileyJack BaileyBoard Member · UNC Health Care